Xiidra vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Miebo | |
|---|---|---|
| Generic name | lifitegrast | perfluorohexyloctane |
| Drug class | LFA-1 Antagonist (Eye Drop) | Semifluorinated Alkane (Eye Drop) |
| Treats | Dry eye disease | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | Bausch + Lomb |
| Year approved | 2016 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $150M | — |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Xiidra or Miebo better?
Neither is universally "better." Xiidra (lifitegrast) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Miebo?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.